	US 11,850,264 B2
	Gamma delta T-cell receptor and its ligand
Andrew Sewell, Cardiff South Glamorgan (GB); and Garry Dolton, Cardiff South Glamorgan (GB)
Assigned to University College Cardiff Consultants Ltd., Cardiff South Wales (GB)
Filed by University College Cardiff Consultants Ltd., Cardiff South Glamorgan (GB)
Filed on May 19, 2020, as Appl. No. 16/877,928.
Application 16/877,928 is a continuation in part of application No. PCT/GB2018/053321, filed on Nov. 16, 2018.
Claims priority of application No. 1719169 (GB), filed on Nov. 20, 2017.
Prior Publication US 2020/0316124 A1, Oct. 8, 2020
Int. Cl. A61K 35/17 (2015.01); C07K 14/725 (2006.01); C12N 7/00 (2006.01); C12N 15/10 (2006.01); C12N 15/86 (2006.01); C07K 14/47 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C12N 7/00 (2013.01); C12N 15/1037 (2013.01); C12N 15/86 (2013.01); A61K 45/06 (2013.01); C12N 2740/15043 (2013.01)]

20 Claims

1. A vector encoding a tumour specific T-cell receptor (TCR), wherein the TCR comprises (i) a γ chain having three y chain complementarity-determining regions (CDRs) comprising the sequences: VTNTFY (SEQ ID NO: 3) as CDR1γ, YDVSTARD (SEQ ID NO: 4) as CDR2γ and CATWDRRDYKKLF (SEQ ID NO: 1) as CDR3γ and (ii) a δ chain having three δ chain CDRs comprising the sequences: TSWWSYY (SEQ ID NO: 5) as CDR1δ, QGS (SEQ ID NO: 6) as CDR2δ and CALGVLPTVTGGGLIF (SEQ ID NO: 2) as CDR3δ.